drugset / Trial / NCT04243551
Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients
Phase 2
Terminated
83 enrolled
Entero Therapeutics
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedCrossoverDouble-blindTreatment
Summary
This is a phase 2b, multicenter, prospective, randomized, double-blind, placebo-controlled, crossover study in symptomatic celiac disease patients attempting a GFD for at least one year prior to screening.
Timeline
- Start
- 2019-11-01
- Primary completion
- 2023-10-16
- Completion
- 2023-10-31
Outcome
Outcome not reported
Stopped (Enrollment): “Due to low enrollment related to Covid.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Latiglutenase | Protein / enzyme biologic | — | Oral |